- Home
- CPT vs EXEL Comparison
CPT vs EXEL Comparison
Compare CPT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPT | EXEL |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 11.1B |
| IPO Year | 1993 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CPT | EXEL |
|---|---|---|
| Price | $104.40 | $44.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 24 |
| Target Price | ★ $119.78 | $44.73 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | ★ 2.47 | 2.38 |
| Revenue | $1,578,428,000.00 | ★ $2,288,218,000.00 |
| Revenue This Year | $2.48 | $9.14 |
| Revenue Next Year | $1.94 | $12.51 |
| P/E Ratio | $42.02 | ★ $18.67 |
| Revenue Growth | 1.41 | ★ 9.93 |
| 52 Week Low | $97.17 | $31.90 |
| 52 Week High | $126.55 | $49.62 |
Technical Indicators
Market Signals| Indicator | CPT | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 63.52 |
| Support Level | $105.68 | $43.00 |
| Resistance Level | $106.77 | $44.79 |
| Average True Range (ATR) | 1.51 | 1.03 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 43.34 | 83.48 |
Price Performance
Historical ComparisonAbout CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.